Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Damora Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 9 | 12 | +3 |
| Shares | 132.8K | 170.2K | +37.4K (+28.2%) |
| Value | $451.5K | $633.3K | +$181.8K (+40.3%) |
New holders (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Connective Capital Management, LLC | 26,956 | $100.3K | 0.09% |
| Two Sigma Investments, LP | 20,296 | $75.5K | 0.00% |
| Virtu Financial LLC | 13,128 | $49.0K | 0.00% |
| Citigroup Inc | 43 | $160 | 0.00% |
Sold out (1)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 13,602 | $45.2K |